LogicBio Therapeutics Net Income | LOGC

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income LogicBio Therapeutics

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-40 M	-32.6 M	-40.1 M	-17.6 M	-5.8 M	-3.43 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-3.43 M	-40.1 M	-23.3 M

Quarterly Net Income LogicBio Therapeutics

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-5.78 M	-5.04 M	-6.66 M	-	-10.2 M	-10.5 M	-10.3 M	-	-8.04 M	-8.23 M	-9.46 M	-	-10.9 M	-10 M	-7.7 M	-	-4.67 M	-3.59 M	-2.3 M	-	-1.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-1.04 M	-10.9 M	-7.15 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	-525 M	-	-	-	Russia
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	1 M	-	-	$ 621 M	Britain
ASLAN Pharmaceuticals Limited ASLN	-44.2 M	-	-14.27 %	$ 1.7 M	Singapore
Revolution Medicines RVMD	-1.13 B	$ 207.32	0.24 %	$ 39.4 B	USA
Rhythm Pharmaceuticals RYTM	-197 K	$ 101.8	0.08 %	$ 6.62 B	USA
Rezolute RZLT	-74.4 M	$ 4.4	0.88 %	$ 334 M	USA
Sana Biotechnology SANA	-244 M	$ 3.45	0.77 %	$ 874 M	USA
Seer SEER	-73.6 M	$ 1.95	0.26 %	$ 108 M	USA
Precigen PGEN	-251 M	$ 6.87	0.14 %	$ 2.15 B	USA
SIGA Technologies SIGA	23.3 M	$ 3.2	1.86 %	$ 229 M	USA
Syndax Pharmaceuticals SNDX	-285 M	$ 19.94	0.05 %	$ 1.73 B	USA
Soligenix SNGX	-11.1 M	$ 0.38	1.18 %	$ 1.97 M	USA
Spruce Biosciences SPRB	-39 M	$ 59.09	2.0 %	$ 45.3 M	USA
Sarepta Therapeutics SRPT	-713 M	$ 20.94	0.04 %	$ 2.1 B	USA
Stoke Therapeutics STOK	-6.88 M	$ 30.05	0.81 %	$ 1.78 B	USA
Sutro Biopharma STRO	-191 M	$ 19.1	0.34 %	$ 162 M	USA
Shattuck Labs STTK	-48.8 M	$ 6.5	0.29 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	-38.6 M	$ 42.43	0.23 %	$ 2.4 B	USA
Savara SVRA	-119 M	$ 5.53	2.98 %	$ 1.23 B	USA
China SXT Pharmaceuticals SXTC	-6.21 M	$ 2.24	0.45 %	$ 1.52 M	China
Takeda Pharmaceutical Company Limited TAK	108 B	$ 18.32	1.49 %	$ 28.9 B	Japan
Bio-Techne Corporation TECH	182 M	$ 72.31	0.01 %	$ 11.3 B	USA
Tenax Therapeutics TENX	-52.6 M	$ 1.98	2.06 %	$ 77.7 M	USA
Teva Pharmaceutical Industries Limited TEVA	1.41 B	$ 36.76	1.21 %	$ 42.1 B	Israel
TG Therapeutics TGTX	447 M	$ 55.74	0.58 %	$ 8.04 B	USA
Trevi Therapeutics TRVI	-42.8 M	$ 16.82	1.17 %	$ 2.27 B	USA
Taysha Gene Therapies TSHA	-109 M	$ 5.48	0.54 %	$ 1.75 B	USA
Sol-Gel Technologies Ltd. SLGL	-6.13 M	$ 69.37	0.35 %	$ 193 M	Israel
UroGen Pharma Ltd. URGN	-153 M	$ 43.82	0.02 %	$ 2.11 B	Israel
United Therapeutics Corporation UTHR	1.33 B	$ 497.97	2.12 %	$ 22.1 B	USA
Spero Therapeutics SPRO	8.57 M	$ 1.19	0.41 %	$ 66.7 M	USA
Scholar Rock Holding Corporation SRRK	-378 M	$ 57.42	3.78 %	$ 6.59 B	USA
Jounce Therapeutics JNCE	-50.9 M	-	-	$ 98.4 M	USA
NextCure NXTC	-55.8 M	$ 8.42	7.67 %	$ 23.9 M	USA
Verrica Pharmaceuticals VRCA	-17.9 M	$ 5.26	0.75 %	$ 56 M	USA
Viridian Therapeutics VRDN	-343 M	$ 23.17	1.09 %	$ 2.36 B	USA
Zosano Pharma Corporation ZSAN	-29.9 M	-	7.23 %	$ 2.72 M	USA
Vertex Pharmaceuticals Incorporated VRTX	3.95 B	$ 528.9	0.22 %	$ 135 B	USA
Verastem VSTM	-209 M	$ 8.08	0.55 %	$ 560 M	USA
vTv Therapeutics VTVT	-27 M	$ 32.79	0.03 %	$ 130 M	USA
Voyager Therapeutics VYGR	-120 M	$ 3.4	3.85 %	$ 200 M	USA
Aravive ARAV	-76.3 M	-	-13.39 %	$ 1.45 M	USA
Wave Life Sciences Ltd. WVE	-204 M	$ 4.91	1.03 %	$ 828 M	Singapore
Tonix Pharmaceuticals Holding Corp. TNXP	-124 M	$ 13.16	0.15 %	$ 112 M	USA
Xenetic Biosciences XBIO	-2.68 M	$ 4.28	0.86 %	$ 7.28 M	USA
XBiotech XBIT	-45.5 M	$ 2.18	0.23 %	$ 66.5 M	USA
Exicure XCUR	-4.95 M	$ 1.41	12.8 %	$ 8.88 M	USA
Xenon Pharmaceuticals XENE	-346 M	$ 59.55	0.18 %	$ 4.72 B	Canada
Xeris Pharmaceuticals XERS	554 K	$ 8.48	0.12 %	$ 1.36 B	USA